English to Russian Science Biology (-tech,-chem,micro-) иммунология�

The primary endpoint of this phase III study was the time to ***platelet count response*** defined as initial platelet count ≥ 150×109/L with subsequent stop of daily PE within 5 days.
The present invention is based on the finding that administration of polypeptides comprising at least one immunoglobulin single variable domain (ISVD) against von Willebrand Factor (vWF) to human patients with a thrombotic thrombocytopenic purpura (TTP) episode, e.g. an initial episode and/or recurrent episode of TTP, results in improved outcomes, including a faster time to ***platelet count response*** lower proportion of patients with either death, recurrence or a major thromboembolic event (TE) during the treatment period, lower recurrence rate, and prevention of refractoriness.